Clinical trials: Genome
Prostate Cancer, Prostate Cancer, Familial
Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a
This study was designed to compare the efficacy, perception, decision making, and cost-effectiveness of genomic and non-genomic approaches for risk assessment of prostate cancer and for chemoprevention of prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer, Familial, Hereditary Prostate Cancer
- Trial name
- NCT02381015
- Testing
- Genetic Risk Score: Number Format, Genetic Risk Score: Number + Pictograph, Family History: Number Format
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Normal Physiology
Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids
Background: The immune system defends the body against bacteria and other harmful invaders. But it can overact and attack healthy cells by mistake.
- Trial name
- NCT02798523
- Testing
- Methylprednisolone sodium succinate(Solu-Medrol), Topical methylprednisolone (Advantan emulsion 0 /1%)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Osteoarthritis, Postoperative Pain
Acute Pain Genomic Study
In preparation for future large-scale genome wide association studies, reliable methods must be developed for measuring perceived pain and for estimating the effects of potentially confounding factors such as appropriate…
- Trial name
- NCT01557751
- Testing
- Whole blood for genotyping
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- University of Pittsburgh
Advanced Unresectable or Metastatic Solid Malignancy
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced…
- Trial name
- MyTACTIC (NCT04632992)
- Testing
- Entrectinib, Inavolisib, Alectinib
- Where
- 38 sites in United States
- Volunteers
- 252 people
- Sponsor
- Genentech, Inc.
Transfusion Dependent Beta-thalassemia
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
This is a single-arm, multi-site, single-dose, Phase 1/2 study to assess ST-400 in 6 subjects with transfusion-dependent β-thalassemia (TDT) who are ≥18 and ≤40 years of age.
- Trial name
- NCT03432364
- Testing
- ST-400 Investigational product
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sangamo Therapeutics
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Whole Genome Sequencing
South-seq: Deoxyribonucleic Acid (DNA) Sequencing for Newborn Nurseries in the South
2,000 infants with signs suggestive of a genetic disorder being treated at a neonatal intensive care unit (NICU) in which African-American and rural populations are highly represented will be enrolled.
- Trial name
- NCT03842995
- Testing
- Genetic Counselor, Trained Healthcare Provider
- Where
- 3 sites in United States
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
This clinical trial studies potential genetic markers which might be used to predict which patients with acute myeloid leukemia or myelodysplastic syndromes respond to decitabine.
- Trial name
- NCT01687400
- Testing
- decitabine
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Washington University School of Medicine
Recurrent Endometrial Cancer
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Primary Objectives: To assess the antitumor activity (proportion of objective response by RECIST 1.1 criteria) of pembrolizumab with objective tumor response in patients with persistent, recurrent or metastatic endometrial cancer…
- Trial name
- NCT02899793
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Cancer of Unknown Primary Site
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have…
- Trial name
- CUPISCO (NCT03498521)
- Testing
- Alectinib, Vismodegib, Ipatasertib
- Where
- 125 sites in Australia, Austria and 31 more
- Volunteers
- 529 people
- Sponsor
- Hoffmann-La Roche
Urothelial Carcinoma, Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Trial name
- NCT02788201
- Testing
- 75 approved agents, COXEN
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Skin Health Online for Melanoma: Better Risk Assessment
This study will have two phases, with an added usability test after Phase I and before Phase 2. Phase 1: Cognitive Interviews of materials in Spanish. Phase 2: Personalized Genomic Testing for Skin Cancer (PGT-SC).
- Trial name
- SOMBRA (NCT03130569)
- Testing
- Web-based Module Group
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Non-small Cell Lung Cancer
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are given with less time between treatments than in standard chemotherapy.
- Trial name
- NCT02157116
- Testing
- cisplatin, Docetaxel, Pegfilgrastim
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Duke University
Influenza
B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
In this exploratory study, investigators will be looking at immune response differences between age groups and between the two different vaccines given to identical twins and vaccine-naive young adults.
- Trial name
- NCT03020537
- Testing
- Fluzone
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Stanford University
Genetic Predisposition
Early Detection of GEnetic Risk (EDGE)
The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers.
- Trial name
- NCT04746794
- Testing
- Population-level screening
- Where
- 2 sites in United States
- Volunteers
- 20,184 people, healthy volunteers welcome
- Sponsor
- University of Washington
Epilepsy; Seizure, Neuromuscular Diseases
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
The "North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family…
- Conditions
- Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability
- Trial name
- NCGENES2 (NCT03548779)
- Testing
- Pre-visit prep, usual care + exome seq
- Where
- 3 sites in United States
- Volunteers
- 548 people
- Sponsor
- University of North Carolina, Chapel Hill
Fetal Structural Anomalies
Prenatal Genetic Diagnosis by Genomic Sequencing
This study is evaluating the impact of prenatal sequencing on the management of fetuses with ultrasound abnormalities. The hypothesis is that a significant subset of fetal abnormalities have a genetic cause that can be identified…
- Trial name
- PrenatalSEQ (NCT03936101)
- Testing
- Prenatal Genomic Sequencing
- Where
- 5 sites in United States
- Volunteers
- 1,097 people, healthy volunteers welcome
- Sponsor
- Columbia University
Triple Negative Breast Neoplasms
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC)…
- Trial name
- NCT02299635
- Testing
- PF-03084014
- Where
- 37 sites in United States, Hungary and 4 more
- Volunteers
- 19 people
- Sponsor
- Pfizer
Hypertension, Chronic Kidney Disease
Genetic Testing to Understand and Address Renal Disease Disparities
In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of…
- Conditions
- Hypertension, Chronic Kidney Disease, Genomics
- Trial name
- GUARDD (NCT02234063)
- Testing
- Immediate Genetic Testing
- Where
- 2 sites in United States
- Volunteers
- 2,052 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Waldenstrom's Macroglobulinemia
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT02604511
- Testing
- Ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute